Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,653 across all filing types
Latest filing 2024-04-19 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
董事会审计委员会关于对会计师事务所2023年度履职情况的评估报告
Audit Report / Information Classification · 95% confidence The document is an evaluation report by the Board Audit Committee on the performance of the accounting firm (立信会计师事务所) for the year 2023. It details the qualifications, independence, quality control, and audit work plan of the auditor for the company's 2023 audit. The document is not the audit report itself but an assessment of the auditor's work and compliance with regulations. It is a standalone audit-related report focusing on the auditor's performance and internal controls, not a full annual report or financial statement. Therefore, it fits the category of Audit Report / Information (AR). The document length is 3410 characters, which is consistent with a detailed audit evaluation report rather than a brief announcement or certification.
2024-04-19 Chinese
关于使用闲置自有资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 贝达药业股份有限公司 regarding the use of idle funds for cash management by investing in low-risk, short-term financial products. It details the investment purpose, amount, risk control measures, and board approval. The document is a formal disclosure of a financing-related activity but does not contain financial statements or detailed financial results. It is not a full financial report, earnings release, or management discussion. It is an update on the company's capital management activities, specifically about the use of idle funds for investment purposes. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is short (2125 characters), and it is not merely an announcement of a report but a substantive disclosure about capital use.
2024-04-19 Chinese
2023年度财务决算报告
Annual Report Classification · 95% confidence The document is titled '2023 年度财务决算报告' which translates to '2023 Annual Financial Settlement Report' and contains detailed financial data for the full year 2023, including income, profit, assets, liabilities, equity, cash flows, and financial ratios. It mentions that the financial accounting report was prepared according to enterprise accounting standards and audited by a certified public accounting firm with an unqualified opinion. The document includes comprehensive financial statements and analysis for the full fiscal year ending December 31, 2023. It also states that the report will be submitted to the shareholders' meeting for approval, indicating it is a formal annual financial report. The length of the document (5567 characters) and the detailed financial content confirm it is the actual annual report rather than an announcement or summary. Therefore, the document fits the definition of an Annual Report (10-K).
2024-04-19 Chinese
2023年度独立董事述职报告（肖佳佳）
Board/Management Information Classification · 95% confidence The document is titled '2023 年度独立董事述职报告' which translates to '2023 Annual Independent Director's Work Report'. It details the independent director's activities, attendance at board and committee meetings, opinions on various company matters, and oversight responsibilities during the year 2023. The content focuses on the director's duties, participation in governance, and compliance with laws and regulations. It does not contain financial statements or audit results but is a report on board/management activities and governance oversight. This fits best under the category of Board/Management Information (MANG), which covers announcements related to changes or reports on the company's board or senior management activities. The document length is sufficient and contains substantive content about the director's role and activities, not just an announcement or certification. Therefore, the classification is MANG with high confidence.
2024-04-19 Chinese
2023年度监事会工作报告
Management Reports Classification · 95% confidence The document is titled '2023 年度监事会工作报告' which translates to '2023 Supervisory Board Work Report'. It details the supervisory board's activities, oversight of company operations, financial status, compliance with laws and regulations, internal controls, and plans for 2024. It includes detailed descriptions of meetings, supervisory activities, and evaluations of financial and governance matters. The document is a comprehensive report on the supervisory board's work for the year 2023, which aligns with the category of Management Reports (MDA) that provide detailed explanations of financial results, business trends, and outlook. It is not an annual report (10-K) or audit report (AR) but a supervisory board's work report, fitting best under Management Reports (MDA). The document length is over 5,000 characters and contains substantive content, not just an announcement or certification, so it is not RPA or RNS.
2024-04-19 Chinese
2024年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '贝达药业股份有限公司 2024 年第一季度报告' which translates to 'Betta Pharmaceuticals Co., Ltd. 2024 First Quarter Report'. It contains detailed financial data including consolidated balance sheets, profit and loss statements, cash flow statements, and management commentary on business operations for the first quarter of 2024. The report explicitly states it is a quarterly report and includes unaudited financial statements for the quarter ending March 31, 2024. The length of the document (14,880 characters) and the presence of substantive financial data confirm it is a full interim/quarterly financial report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2024-04-19 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.